A
Andreas Block
Researcher at University of Hamburg
Publications - 29
Citations - 1924
Andreas Block is an academic researcher from University of Hamburg. The author has contributed to research in topics: Genetic enhancement & Cancer. The author has an hindex of 10, co-authored 25 publications receiving 1107 citations. Previous affiliations of Andreas Block include Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Thorsten Oliver Goetze,Johannes Meiler,Stefan Kasper,Hans-Georg Kopp,Frank Mayer,Georg Martin Haag,Kim Barbara Luley,U. Lindig,Wolff Schmiegel,Michael Pohl,Jan Stoehlmacher,Gunnar Folprecht,Stephan Probst,Nicole Prasnikar,Wolfgang Fischbach,Rolf Mahlberg,Jörg Trojan,Michael Koenigsmann,Uwe M. Martens,Peter C. Thuss-Patience,Matthias Egger,Andreas Block,Volker Heinemann,Gerald Illerhaus,Markus Moehler,Michael Schenk,Frank Kullmann,Dirk M Behringer,Michael Heike,Daniel Pink,Christian Teschendorf,Carmen Löhr,Helga Bernhard,G. Schuch,Volker Rethwisch,Ludwig Fischer von Weikersthal,Jörg T. Hartmann,Michael Kneba,Severin Daum,Karsten Schulmann,Jörg Weniger,Sebastian Belle,Timo Gaiser,Fuat Oduncu,Martina Güntner,Wael Hozaeel,Alexander Reichart,Elke Jäger,Thomas Kraus,Stefan Mönig,Wolf O. Bechstein,Martin Schuler,Harald Schmalenberg,Ralf Hofheinz,Flot Aio Investigators +57 more
TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.
Journal ArticleDOI
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Salah-Eddin Al-Batran,Ralf Hofheinz,Claudia Pauligk,Hans-Georg Kopp,Georg Martin Haag,Kim Barbara Luley,Johannes Meiler,Nils Homann,Sylvie Lorenzen,Harald Schmalenberg,Stephan Probst,Michael Koenigsmann,Matthias Egger,Nicole Prasnikar,Karel Caca,Jörg Trojan,Uwe M. Martens,Andreas Block,Wolfgang Fischbach,Rolf Mahlberg,Michael R. Clemens,Gerald Illerhaus,Katja Zirlik,Dirk Behringer,Wolff Schmiegel,Michael Pohl,Michael Heike,Ulrich Ronellenfitsch,Martin Schuler,Wolf O. Bechstein,Alfred Königsrainer,Timo Gaiser,Peter Schirmacher,Wael Hozaeel,Alexander Reichart,Thorsten Oliver Goetze,Mark Sievert,Elke Jäger,Stefan Mönig,Andrea Tannapfel +39 more
TL;DR: Findings from the phase 2 part of the FLOT4 trial, which compared histopathological regression in patients treated with a docetaxel-based triplet chemotherapy versus an anthracycline-based doublet chemotherapy before surgical resection, suggest FLOT was associated with significantly higher proportions of patients achieving pathological complete regression than was ECF/ECX.
Journal ArticleDOI
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study
Arndt Vogel,Stefan Kasper,Michael Bitzer,Andreas Block,Marianne Sinn,Henning Schulze-Bergkamen,Markus Moehler,Nicole Pfarr,Nicole Pfarr,Volker Endris,Benjamin Goeppert,Kirsten Merx,Elisabeth Schnoy,Jens T. Siveke,Patrick Michl,Dirk Waldschmidt,Jan Kuhlmann,Michael Geissler,Christoph Kahl,Ralph Evenkamp,Torben Schmidt,Alexander Kuhlmann,Wilko Weichert,Wilko Weichert,Wilko Weichert,Stefan Kubicka +25 more
TL;DR: Panitumumab in combination with chemotherapy does not improve ORR, PFS and OS in patients with KRAS wild-type, advanced biliary cancer and genetic alterations in IDH1/2 were linked to a high response after chemotherapy and prolonged survival.
Journal ArticleDOI
Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg.
Katja Weisel,Andrea Morgner-Miehlke,Cordula Petersen,Walter Fiedler,Andreas Block,Philippe Schafhausen,Johannes K.-M. Knobloch,Carsten Bokemeyer +7 more
TL;DR: Support and potential perspectives are provided to generate a discussion basis on how to maintain high-end cancer care during such a crisis and how to conduct patients safely into the future.
Journal Article
Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors.
Andreas Block,Dragan Milasinovic,Juergen Mueller,Peter Schaefer,Hansjoerg Schaefer,Heiner Greten +5 more
TL;DR: These new adenoviral vectors combing highly efficient and specific transgene expression will contribute to the safety and efficacy of experimental approaches in cancer gene therapy and will contribute To overcome weak expression, which is much lower than the widely used cytomegalovirus-promoter.